Text Size

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: A meta-analysis of two phase IIIb clinical trials

Uusitalo H., Egorov E., Kaarniranta K., Astakhov Y., Ropo A.


  • 2016
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russian Federation; Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russian Federation; Global Medical Affairs, Santen Oy, Tampere, Finland

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022